Treatment of gastrointestinal motility disorders
(selective serotonin 5HT4antagonist).
ChEBI: Tegaserod is a member of guanidines, a carboxamidine, a member of hydrazines and a member of indoles. It has a role as a serotonergic agonist and a gastrointestinal drug.
Tegaserod (Zelnorm) is serotonin-4 (5-HT4) receptor agonists that stimulate GI motility.
Tegaserod is being developed as a treatment for constipation-
predominant irritable bowel syndrome (IBS).
Within the first week, patients treated with tegaserod
had significant improvements in abdominal pain and discomfort,
constipation, and overall well-being. Efficacy
was maintained throughout the treatment period.
Tegaserod also demonstrated significant improvements
in the three bowel-related assessments (stool frequency,
stool consistency, and straining) within the first week,
and these improvements were sustained throughout the
treatment period. The most common adverse events reported
thus far are headache and diarrhea.
